Allergy Asthma Immunol Res.  2011 Apr;3(2):74-80. 10.4168/aair.2011.3.2.74.

Gender-Specific Asthma Treatment

• Choi IS

• KMID: 2130357
• DOI: http://doi.org/10.4168/aair.2011.3.2.74

Abstract

Because genetic characteristics vary among subjects, the therapeutic effects of a certain drug differ among patients with the same disease. For this reason, special interest has focused on tailored treatments. Although it is well known that sex is genetically determined, little attention has been paid to sex differences in the clinical features and treatment of asthma. Females are more likely to suffer allergic asthma, to have difficulty controlling asthma symptoms, and to show adverse effects to drugs. As asthma symptoms show cyclic changes depending on female hormone levels in many women of child-bearing age, the use of contraceptives may specifically help to treat female patients with asthma such as those with perimenstrual asthma and severe asthma. Generally, testosterone seems to suppress asthma, and dehydroepiandrosterone (DHEA), a less virilizing androgen, may be effective for treating asthma. Evidence exists for a therapeutic and steroid-sparing effect of DHEA. However, further studies on the optimal dose and route of DHEA for each sex are needed. Monitoring of the serum DHEA-S level is necessary for patients with asthma on inhaled steroid treatment, and at minimum, replacement therapy for patients with a low level of DHEA may be helpful for treating their asthma.

Keyword

Asthma; dehydroepiandrosterone; sex; perimenstrual; treatment

MeSH Terms

Asthma
Contraceptive Agents
Dehydroepiandrosterone
Female
Humans
Sex Characteristics
Testosterone
Contraceptive Agents
Dehydroepiandrosterone
Testosterone

Figure

• 

  Figure Sex differences in asthma prevalence. The ratios of female to male patients with asthma and a positive response to skin prick tests using house dust mites (HDM) (redrawn from Wormald6) and in patients who were reported to have asthma in the European Community Respiratory Health Survey (ECRHS) (redrawn from de Marco et al.7), and the number of asthma patients per 100 population for each sex in the General Practice Research Database (redrawn from Osman et al.8).

Reference

1. Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma. updated 2009. Available from: http://www.ginasthma.org.

2. Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY, Park HS. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics. 2007. 8:1143–1150.

3. Osman M. Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child. 2003. 88:587–590.

4. Almqvist C, Worm M, Leynaert B. working group of GA²LEN WP 2.5 'Gender'. Impact of gender on asthma in childhood and adolescence: a GA²LEN review. Allergy. 2008. 63:47–57.

5. Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy. 2008. 63:1418–1427.

6. Wormald PJ. Age-sex incidence in symptomatic allergies: an excess of females in the child-bearing years. J Hyg (Lond). 1977. 79:39–42.

7. de Marco R, Locatelli F, Sunyer J, Burney P. Differences in incidence of reported asthma related to age in men and women. A retrospective analysis of the data of the European Respiratory Health Survey. Am J Respir Crit Care Med. 2000. 162:68–74.

8. Osman M, Hansell AL, Simpson CR, Hollowell J, Helms PJ. Gender-specific presentations for asthma, allergic rhinitis and eczema in primary care. Prim Care Respir J. 2007. 16:28–35.

9. Poulos LM, Waters AM, Correll PK, Loblay RH, Marks GB. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol. 2007. 120:878–884.

10. Nicolai T, Pereszlenyiova-Bliznakova L, Illi S, Reinhardt D, von Mutius E. Longitudinal follow-up of the changing gender ratio in asthma from childhood to adulthood: role of delayed manifestation in girls. Pediatr Allergy Immunol. 2003. 14:280–283.

11. Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy. 1993. 23:941–948.

12. Postma DS. Gender differences in asthma development and progression. Gend Med. 2007. 4:Suppl B. S133–S146.

13. Nowak RM, Tomlanovich MC, Sarkar DD, Kvale PA, Anderson JA. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA. 1983. 249:2043–2046.

14. Salam MT, Wenten M, Gilliland FD. Endogenous and exogenous sex steroid hormones and asthma and wheeze in young women. J Allergy Clin Immunol. 2006. 117:1001–1007.

15. Kalogeromitros D, Katsarou A, Armenaka M, Rigopoulos D, Zapanti M, Stratigos I. Influence of the menstrual cycle on skin-prick test reactions to histamine, morphine and allergen. Clin Exp Allergy. 1995. 25:461–466.

16. Mandhane PJ, Hanna SE, Inman MD, Duncan JM, Greene JM, Wang HY, Sears MR. Changes in exhaled nitric oxide related to estrogen and progesterone during the menstrual cycle. Chest. 2009. 136:1301–1307.

17. Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med. 1997. 155:1273–1277.

18. Mitchell VL, Gershwin LJ. Progesterone and environmental tobacco smoke act synergistically to exacerbate the development of allergic asthma in a mouse model. Clin Exp Allergy. 2007. 37:276–286.

19. Hamano N, Terada N, Maesako K, Hohki G, Ito T, Yamashita T, Konno A. Effect of female hormones on the production of IL-4 and IL-13 from peripheral blood mononuclear cells. Acta Otolaryngol Suppl. 1998. 537:27–31.

20. Holt PG, Britten D, Sedgwick JD. Suppression of IgE responses by antigen inhalation: studies on the role of genetic and environmental factors. Immunology. 1987. 60:97–102.

21. Vasiadi M, Kempuraj D, Boucher W, Kalogeromitros D, Theoharides TC. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol. 2006. 19:787–794.

22. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, Zhao L, An X, Du X, Chen X, Wang S, Xia G, Wang B. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. 2008. 214:456–464.

23. van den Berge M, Heijink HI, van Oosterhout AJ, Postma DS. The role of female sex hormones in the development and severity of allergic and non-allergic asthma. Clin Exp Allergy. 2009. 39:1477–1481.

24. Jenkins MA, Dharmage SC, Flander LB, Douglass JA, Ugoni AM, Carlin JB, Sawyer SM, Giles GG, Hopper JL. Parity and decreased use of oral contraceptives as predictors of asthma in young women. Clin Exp Allergy. 2006. 36:609–613.

25. Barr RG, Wentowski CC, Grodstein F, Somers SC, Stampfer MJ, Schwartz J, Speizer FE, Camargo CA Jr. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. Arch Intern Med. 2004. 164:379–386.

26. Melgert BN, Postma DS, Kuipers I, Geerlings M, Luinge MA, van der Strate BW, Kerstjens HA, Timens W, Hylkema MN. Female mice are more susceptible to the development of allergic airway inflammation than male mice. Clin Exp Allergy. 2005. 35:1496–1503.

27. Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD. Effect of medical castration on CD4⁺ CD25⁺ T cells, CD8⁺ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006. 290:E856–E863.

28. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, Samuelsson B, Rådmark O, Sautebin L, Werz O. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A. 2008. 105:19881–19886.

29. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology. 2000. 100:384–390.

30. Dunn PJ, Mahood CB, Speed JF, Jury DR. Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study. N Z Med J. 1984. 97:805–808.

31. Tabata N, Tagami H, Terui T. Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis. Arch Dermatol Res. 1997. 289:410–414.

32. Kannisto S, Korppi M, Remes K, Voutilainen R. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2001. 86:4908–4912.

33. Global obesity prevalence in adults [Internet]. International Obesity Task Force. Available from: http://www.iotf.org.

34. Lovejoy JC, Sainsbury A. Stock Conference 2008 Working Group. Sex differences in obesity and the regulation of energy homeostasis. Obes Rev. 2009. 10:154–167.

35. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol. 2005. 115:897–909.

36. Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med. 1999. 159:2582–2588.

37. Delgado J, Barranco P, Quirce S. Obesity and asthma. J Investig Allergol Clin Immunol. 2008. 18:420–425.

38. Lugogo NL, Kraft M, Dixon AE. Does obesity produce a distinct asthma phenotype? J Appl Physiol. 2010. 108:729–734.

39. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008. 178:682–687.

40. Yoo S, Kim HB, Lee SY, Kim BS, Kim JH, Yu JH, Kim BJ, Hong SJ. Association between obesity and the prevalence of allergic diseases, atopy, and bronchial hyperresponsiveness in Korean adolescents. Int Arch Allergy Immunol. 2010. 154:42–48.

41. Jeon YH, Yang HJ, Pyun BY. Lung function in Korean adolescent girls: in association with obesity and the menstrual cycle. J Korean Med Sci. 2009. 24:20–25.

42. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010. 375:2267–2277.

43. Pereira Vega A, Sánchez Ramos JL, Maldonado Pérez JA, Alvarez Gutierrez FJ, Ignacio García JM, Vázquez Oliva R, Romero Palacios P, Bravo Nieto JM, Sánchez Rodríguez I, Gil Muñoz F. Variability in the prevalence of premenstrual asthma. Eur Respir J. 2010. 35:980–986.

44. Jensen-Jarolim E, Untersmayr E. Gender-medicine aspects in allergology. Allergy. 2008. 63:610–615.

45. Frank RT. The hormonal cause of premenstrual tension. Arch Neurol Psychiatry. 1931. 26:1053–1057.

46. Dratva J, Schindler C, Curjuric I, Stolz D, Macsali F, Gomez FR, Zemp E. SAPALDIA Team. Perimenstrual increase in bronchial hyperreactivity in premenopausal women: results from the population-based SAPALDIA 2 cohort. J Allergy Clin Immunol. 2010. 125:823–829.

47. Svanes C, Real FG, Gislason T, Jansson C, Jögi R, Norrman E, Nyström L, Torén K, Omenaas E. Association of asthma and hay fever with irregular menstruation. Thorax. 2005. 60:445–450.

48. Luskin AT, Lipkowitz MA. The diagnosis and management of asthma during pregnancy. Immunol Allergy Clin North Am. 2000. 20:745–761.

49. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005. 115:233–242.

50. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007. 120:e702–e712.

51. de Benedictis FM, Baraldi E, Boner A. Gender differences in the effectiveness of asthma treatment. Pediatrics. 2008. 121:1289.

52. Cui Y, Choi IS, Koh YA, Lin XH, Cho YB, Won YH. Effects of combined BCG and DHEA treatment in preventing the development of asthma. Immunol Invest. 2008. 37:191–202.

53. Igarashi T, Iwakawa S. Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. Biol Pharm Bull. 2009. 32:304–307.

54. Sundberg R, Torén K, Franklin KA, Gislason T, Omenaas E, Svanes C, Janson C. Asthma in men and women: treatment adherence, anxiety, and quality of sleep. Respir Med. 2010. 104:337–344.

55. Hermosa JL, Sánchez CB, Rubio MC, Mínguez MM, Walther JL. Factors associated with the control of severe asthma. J Asthma. 2010. 47:124–130.

56. Park MA, Matesic D, Markus PJ, Li JT. Female sex as a risk factor for penicillin allergy. Ann Allergy Asthma Immunol. 2007. 99:54–58.

57. Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009. 41:408–421.

58. Ishizuka T, Hisada T, Aoki H, Yanagitani N, Kaira K, Utsugi M, Shimizu Y, Sunaga N, Dobashi K, Mori M. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. Allergy Asthma Proc. 2007. 28:550–556.

59. Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010. 224:305–310.

60. Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE. GL601 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002. 46:1820–1829.

61. Shah S. European Respiratory Society--14th Annual Congress. Drug highlights. 4-8 September 2004, Glasgow, UK. IDrugs. 2004. 7:914–916.

62. Arlt W. Dehydroepiandrosterone replacement therapy. Curr Opin Endocrinol Diabetes. 2006. 13:291–305.

63. Lin XH, Choi IS, Koh YA, Cui Y. Effects of combined bacille Calmette-Guerin and dehydroepiandrosterone treatment on established asthma in mice. Exp Lung Res. 2009. 35:250–261.

64. Choi IS, Cui Y, Koh YA, Lee HC, Cho YB, Won YH. Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics. Korean J Intern Med. 2008. 23:176–181.

65. Cheng GF, Tseng J. Regulation of murine interleukin-10 production by dehydroepiandrosterone. J Interferon Cytokine Res. 2000. 20:471–478.

66. Hernandez-Pando R, De La Luz Streber M, Orozco H, Arriaga K, Pavon L, Al-Nakhli SA, Rook GA. The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology. 1998. 95:234–241.

67. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther. 1998. 285:876–883.

68. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor α and interleukin-6 in astrocytes. Int J Dev Neurosci. 1999. 17:765–775.

69. Corporate overview [Internet]. Epigenesis Pharmaceuticals. Available from: http://www.epigene.com/about/overview.html.

70. Nyce JW. Liquid inhalation formulations of dehydroepiandrosterone derivatives [Internet]. Available from: http://www.faqs.org/patents/app/20090053143.